年轻发病的认知障碍和痴呆症 帕金森病
Diego Santos-García1,2, Teresa de Deus Fonticoba3, Carlos Cores Bartolomé4
1CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. diegosangar@yahoo.es.
Journal of neurology
|August 14, 2023
概括
年轻发病的帕金森病 (YOPD) 患者表现出比晚发病患者慢的认知衰退. 这项研究强调了YOPD个体在四年内保持认知功能.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
背景情况:
- 年轻发病的帕金森病 (YOPD) 的特点是疾病进展较慢.
- 与晚期发病的帕金森病 (PD) 相比,YOPD的认知功能变化需要进一步调查.
研究的目的:
- 分析和比较YOPD患者与非YOPD患者和健康对照者的认知功能的进展.
- 在YOPD中识别认知障碍的预测因子.
主要方法:
- 在COPPADIS队列中使用帕金森病认知评分表 (PD-CRS) 评估认知功能,持续4年.
- 根据症状发作的年龄,患者被分为YOPD (<50岁) 和非YOPD (≥50岁) 患者.
- 认知障碍 (CI) 被定义为PD-CRS得分<81,痴呆症 (≤64) 和轻度认知障碍 (MCI) (65-80) 分类.
主要成果:
- 与非YOPD患者和对照人群相比,YOPD患者在所有时间点都表现出明显更高的PD-CRS得分 (p<0.0001).
- 在YOPD患者和对照组中,认知功能保持稳定,而非YOPD患者在4年内表现出显著的认知衰退 (p<0.0001).
- 在4年后,老年OPD患者的痴呆和MCI患病率明显较低 (5%和10%),而不是非老年OPD患者 (25.2%和22.3%;p<0.0001). 较低的基线帕金森病睡眠度量得分预测了YOPD中的CI.
结论:
- 在年轻发病的帕金森病中,认知功能障碍的进展速度明显较慢,而不是晚发病.
- 在4年的随访期间,YOPD患者的认知功能与对照人群相提并论.
- 睡眠障碍可能是YOPD认知能力下降的早期指标.
相关概念视频
Parkinson's Disease: Overview
598
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
598
Parkinson's Disease: Treatment
299
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
299
Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215


